Abiopharma

🔍 Ellenbogen Michael (Director)

Company: Evolv Technologies Holdings, Inc. (EVLV)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 80,745 shares of Class A Common Stock at $0.24 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,164,706.00 | transaction_form_type: 4
• Sold 80,745 shares of Class A Common Stock at $6.32 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,083,961.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: Held by Family Horizon Trust | shares_owned_after: 151,135.00
• Sold 80,745 shares of Stock Option (Right to Buy) at $0.24 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2027-09-13 | equity_swap_involved: 0 | shares_owned_after: 1,139,249.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 12, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.39. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The option vested and become exercisable as to 25% on January 31, 2018 and vested in 36 equal monthly installments thereafter.